Based on the key indicators related to Codexis' liquidity, profitability, solvency, and operating efficiency, Codexis is not in a good financial situation at this time. It has a very high probability of going through financial hardship in February. At this time, Codexis' Accumulated Other Comprehensive Income is comparatively stable compared to the past year. Short Term Investments is likely to gain to about 51.2 M in 2026, whereas Other Current Liabilities is likely to drop slightly above 14.6 M in 2026.
Investors should never underestimate Codexis' ability to pay suppliers on time, ensure interest payments are not accumulating, and correctly time where and how to reinvest extra cash. Individual investors need to monitor Codexis' cash flow, debt, and profitability to make informed and accurate decisions about investing in Codexis.
Understanding current and past Codexis Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Codexis' financial statements are interrelated, with each one affecting the others. For example, an increase in Codexis' assets may result in an increase in income on the income statement.
Please note, the imprecision that can be found in Codexis' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Codexis. Check Codexis' Beneish M Score to see the likelihood of Codexis' management manipulating its earnings.
Codexis Stock Summary
Codexis competes with OmniAb, Sangamo Therapeutics, Insight Molecular, C4 Therapeutics, and Rani Therapeutics. Codexis, Inc. discovers, develops, and sells enzymes and other proteins. The company was incorporated in 2002 and is headquartered in Redwood City, California. Codexis operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 261 people.
Specialization
Health Care, Pharmaceuticals, Biotechnology & Life Sciences
The reason investors look at the income statement is to determine what Codexis' earnings per share (EPS) will be in order to see if they want to buy more shares or not. For example, if a company earned $20 million in the last quarter and has 100,000 shares outstanding, its EPS is 20 cents. If you find that this number beats analysts' forecasts or is higher than it was from the same period last year, then you might want to buy more of this stock even though its price per share may not have changed.
Comparative valuation techniques use various fundamental indicators to help in determining Codexis's current stock value. Our valuation model uses many indicators to compare Codexis value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Codexis competition to find correlations between indicators driving Codexis's intrinsic value. More Info.
Codexis is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . At this time, Codexis' Return On Equity is comparatively stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value Codexis by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.
Most indicators from Codexis' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Codexis current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Codexis. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in median.
Today, most investors in Codexis Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Codexis' growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Codexis growth as a starting point in their analysis.
Along with financial statement analysis, the daily predictive indicators of Codexis help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Codexis. We use our internally-developed statistical techniques to arrive at the intrinsic value of Codexis based on widely used predictive technical indicators. In general, we focus on analyzing Codexis Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Codexis's daily price indicators and compare them against related drivers.
When running Codexis' price analysis, check to measure Codexis' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Codexis is operating at the current time. Most of Codexis' value examination focuses on studying past and present price action to predict the probability of Codexis' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Codexis' price. Additionally, you may evaluate how the addition of Codexis to your portfolios can decrease your overall portfolio volatility.